Mar 28 |
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
|
Mar 28 |
Earnings Scheduled For March 28, 2024
|
Mar 27 |
Achieve Life Sciences Q4 2023 Earnings Preview
|
Mar 20 |
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
|
Mar 8 |
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
|
Mar 5 |
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
|
Feb 29 |
Achieve Life Sciences stock falls 11% amid FDA update, securities sale
|
Feb 29 |
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
|
Feb 29 |
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
|
Jan 27 |
Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) market cap touched US$109m last week, benefiting both retail investors who own 59% as well as institutions
|